ArticleBMC pediatrics2026
Predictors of adverse outcome in infants with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia: a real-world cohort study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo identify robust predictors of adverse outcomes in infants with hypoxic-ischemic encephalopathy (HIE) from a real-world referral center cohort, using readily available clinical characteristics, biochemical markers, electroencephalography (EEG), and cranial magnetic resonance imaging (MRI), and to develop a practical prediction approach applicable to diverse settings, particularly in low- and middle-income countries (LMICs).
methodsWe conducted a retrospective cohort study of 116 infants with HIE who underwent therapeutic hypothermia (TH). Clinical features, biochemical parameters, EEG data, and MRI findings were analyzed. MRI lesions were assessed using a modified MRI scoring system, and neurodevelopmental outcomes were evaluated at 2 years of age. Variables with P < 0.05 in the univariate analysis, selected based on established clinical relevance and previously published evidence, were entered into the multivariate logistic regression model to identify independent factors associated with adverse outcomes. Receiver operating characteristic (ROC) curve analysis was performed to assess predictive performance.
resultsAmong the 116 infants, 32 (27.6%) experienced adverse outcomes, including 20 deaths (17.2%). In multivariate analysis, the gray matter (GM) subscore on MRI emerged as the sole independent predictor of adverse outcomes (OR 1.6, 95% CI 1.3-2.1). A GM subscore ≥ 9 demonstrated excellent predictive accuracy, with an area under the ROC curve of 0.96, sensitivity of 84.4%, and specificity of 100%.
conclusionThe GM subscore is a practical and reliable independent predictor of adverse neurodevelopmental outcomes at 2 years of age in infants with HIE treated with TH, making it a valuable prognostic tool with significant clinical implications, particularly in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.